Department of Medicine (Y.W., T.Y., C.M.S., L.L.D., A.M.G., G.E.D.), Vanderbilt University Medical Center, Nashville, TN.
Vanderbilt Institute for Clinical and Translational Research (B.D.L., E.H.F.-E.), Vanderbilt University Medical Center, Nashville, TN.
Circulation. 2022 Jan 25;145(4):299-308. doi: 10.1161/CIRCULATIONAHA.121.054883. Epub 2022 Jan 7.
Multiple reports associate the cardiac sodium channel gene () variants S1103Y and R1193Q with type 3 congenital long QT syndrome and drug-induced long QT syndrome. These variants are too common in ancestral populations to be highly arrhythmogenic at baseline, however: S1103Y allele frequency is 8.1% in African Americans and R1193Q 6.1% in East Asians. R1193Q is known to increase late sodium current () in cardiomyocytes derived from induced pluripotent stem cells but the role of these variants in modulating repolarization remains poorly understood.
We determined the effect of S1103Y on QT intervals among African-American participants in a large electronic health record. Using cardiomyocytes derived from induced pluripotent stem cells carrying naturally occurring or genome-edited variants, we studied action potential durations (APDs) at baseline and after challenge with the repolarizing potassium current () blocker dofetilide and and at baseline.
In 1479 African-American participants with no confounding medications or diagnoses of heart disease, QT intervals in S1103Y carriers was no different from that in noncarriers. Baseline APD was no different in cells expressing the Y allele (SY, YY cells) compared with isogenic cells with the reference allele (SS cells). However, was increased in SY and YY cells and the blocker GS967 shortened APD in SY/YY but not SS cells (<0.001). was increased almost 2-fold in SY/YY cells compared with SS cells (tail current: 0.66±0.1 versus 1.2±0.1 pA/pF; <0.001). Dofetilide challenge prolonged APD at much lower concentrations in SY (4.1 nmol/L [interquartile range, 1.5-9.3]; n=11) and YY (4.2 nmol/L [1.7-5.0]; n=5) than in SS cells (249 nmol/L [22.3-2905]; n=14; <0.001 and <0.01, respectively) and elicited afterdepolarizations in 8/16 SY/YY cells but only in 1/14 SS cells. R1193Q cells similarly displayed no difference in baseline APD but increased I and increased dofetilide sensitivity.
These common ancestry-specific variants do not affect baseline repolarization, despite generating increased . We propose that increased serves to maintain normal repolarization but increases the risk of manifest QT prolongation with block in variant carriers. Our findings emphasize the need for inclusion of diverse populations in the study of adverse drug reactions.
多项报告将心脏钠离子通道基因()的 S1103Y 和 R1193Q 变异与 3 型先天性长 QT 综合征和药物诱导的长 QT 综合征相关联。这些变异在祖先群体中太常见了,因此在基线时不会具有高度致心律失常性:S1103Y 等位基因频率在非裔美国人中为 8.1%,在东亚人中为 6.1%。已知 R1193Q 会增加诱导多能干细胞衍生的心肌细胞中的晚期钠电流(),但这些变异在调节复极化方面的作用仍知之甚少。
我们确定了 S1103Y 在大型电子健康记录中非洲裔美国参与者的 QT 间期中的作用。使用携带天然或基因组编辑变异的诱导多能干细胞衍生的心肌细胞,我们研究了在复极化钾电流()阻滞剂地尔硫䓬和 以及 存在时的动作电位持续时间(APD)。
在 1479 名无混杂药物或心脏病诊断的非裔美国参与者中,S1103Y 携带者的 QT 间期与非携带者没有差异。与具有参考等位基因的同基因细胞(SS 细胞)相比,表达 Y 等位基因的细胞(SY、YY 细胞)的基础 APD 没有差异。然而,在 SY 和 YY 细胞中,I 和 阻滞剂 GS967 缩短了 APD(<0.001)。与 SS 细胞相比,SY/YY 细胞中的 I 增加了近 2 倍(尾电流:0.66±0.1 对 1.2±0.1 pA/pF;<0.001)。地尔硫䓬挑战以远低于 SS 细胞(4.1 nmol/L [四分位间距,1.5-9.3];n=11)和 YY 细胞(4.2 nmol/L [1.7-5.0];n=5)的浓度延长了 SY(<0.001 和 <0.01)和 YY 细胞的 APD,并且在 8/16 的 SY/YY 细胞中引发了后除极,但仅在 1/14 的 SS 细胞中引发。R1193Q 细胞的基础 APD 也没有差异,但 I 增加,对地尔硫䓬的敏感性增加。
尽管产生了增加的 I,但这些常见的与祖先特异性相关的变异并不影响基础复极。我们提出,增加的 I 有助于维持正常复极,但会增加变异携带者中明显 QT 延长的风险。我们的研究结果强调了在研究药物不良反应时纳入不同人群的必要性。